The transforming EML4-ALK fusion transcript was initially detected in approximately 7% of patients with non-small-cell lung cancer (NSCLC) (66), with the fusion being mutually exclusive with the better-known EGFR mutations. The gene discussed is ALK; the disease is non-small cell lung carcinoma.